Open AccessFormulation and evaluation of voriconazole ophthalmic solid lipid nanoparticles in situ gel
Author(s) -
Dinesh Kumar Pandurangan,
Prathima Bodagala,
Vijayaraj Kumar Palanirajan,
Saravanan Govindaraj
Publication year - 2016
Publication title -
international journal of pharmaceutical investigation
Language(s) - English
Resource type - Journals
eISSN - 2230-973X
pISSN - 2230-9713
DOI - 10.4103/2230-973x.176488
Subject(s) - solid lipid nanoparticle , in situ , materials science , nanoparticle , voriconazole , nanotechnology , chemical engineering , chemistry , medicine , organic chemistry , dermatology , antifungal , engineering
In the present investigation, solid lipid nanoparticles (SLNs)-loaded in situ gel with voriconazole drug was formulated. Further, the formulation was characterized for pH, gelling capacity, entrapment efficiency, in vitro drug release, drug content, and viscosity. Voriconazole is an antifungal drug used to treat various infections caused by yeast or other types of fungi. Film hydration technique was used to prepared SLNs from lecithin and cholesterol. Based on the entrapment efficiency 67.2-97.3% and drug release, the optimized formulation NF1 of SLNs was incorporated into in situ gels. The in situ gels were prepared using viscosity-enhancing polymers such as Carbopol and (hydroxypropyl)methyl cellulose (HPMC). Formulated SLN in situ gel formulations were characterized, which showed pH 4.9-7.1, drug content 65.69-96.3%, and viscosity (100 rpm) 120-620 cps. From the characterizations given above, F6 was optimized and evaluated for microbial assay and ocular irritation studies. Microbial assay was conducted by the cup-plate method using Candida albicans as the test organism. An ocular irritation study was conducted on albino rabbits. The results revealed that there was no ocular damage to the cornea, conjunctiva, or iris. Stability studies were carried out on the F6 formulation for 3 months, which showed that the formulation had good stability. These results indicate that the studied SLNs-loaded in situ gel is a promising vehicle for ocular delivery.